BMRA Pengajuan SEC - Biomerica, Inc.- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

CIK

73290

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Biomerica, Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

August 29, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 For The Fiscal Year Ended May 31, 2025 or ☐ Transition Report Pursuant to Section UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 For The Fiscal Year Ended May 31, 2025 or ☐ Transition Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 For The Transition Period From To Commission File Number: 001-37863 BIOMERICA, INC. (Exact Name of
June 6, 2025	EX-99.1	Biomerica Appoints Eric B. Chin to Board of Directors and Audit Committee Chair Exhibit 99.1 NEWS - For Immediate Release Biomerica Appoints Eric B. Chin to Board of Directors and Audit Committee Chair - Mr. Chin brings over 20 years of financial experience across public and private healthcare organizations - Mr. Chin currently serves as CFO of Akido Labs where he successfully helped raise $60 million in a recent financing - Mr. Chin’s appointment strengthens Biomerica’s corp
June 6, 2025	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2025 BIOMERICA, INC.
April 16, 2025	EX-99.1	Biomerica Announces Reverse Stock Split Exhibit 99.1 Biomerica Announces Reverse Stock Split Shares Expected to Begin Trading on Split-Adjusted Basis on April 21, 2025 IRVINE, Calif., April 16, 2025 (GLOBE NEWSWIRE) – Biomerica, Inc. (NASDAQ: BMRA) (“Biomerica”), a global provider of advanced medical products, today announced that it will implement a 1-for-8 reverse stock split of the issued and outstanding shares of its common stock (t
April 16, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2025 BIOMERICA, INC. (Exa UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2025 BIOMERICA, INC.
April 16, 2025	EX-3.1	CERTIFICATE OF AMENDMENT OF THE SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION BIOMERICA, INC. Adopted in accordance with the provisions of Section 242 of the General Corporation Law of the State of Delaware Exhibit 3.1 CERTIFICATE OF AMENDMENT OF THE SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BIOMERICA, INC. Adopted in accordance with the provisions of Section 242 of the General Corporation Law of the State of Delaware Biomerica, Inc. (the “Corporation”), a corporation organized and existing under the laws of the State of Delaware, by its duly authorized officer, does hereby certify:
April 14, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED FEBRUARY 28, 2025 or ☐ TRANSITION REPORT PURSUA UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED FEBRUARY 28, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37863 BIOMERICA, INC. (Exact name of registrant as specif
January 14, 2025	EX-10.2	Employment Agreement dated January 13, 2025 by and between Biomerica Inc. and Allen Barbieri Exhibit 10.2 BIOMERICA, INC. Employment Agreement This Employment Severance Agreement (the “Agreement”) is entered into by and between Biomerica, Inc., a California Corporation (the “Company”) and Allen Barbieri (“Employee”). The parties agree that Employee’s employment with the Company is subject to and shall be governed by the following terms and conditions: 1. Duties and Scope of Employment. a.
January 14, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED NOVEMBER 30, 2024 or ☐ TRANSITION REPORT PURSUA UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED NOVEMBER 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37863 BIOMERICA, INC. (Exact name of registrant as specif
January 14, 2025	EX-10.1	Employment Agreement dated January 13, 2025 by and between Biomerica Inc. and Zackary S. Irani Exhibit 10.1 BIOMERICA, INC. Employment Agreement This Employment Severance Agreement (the “Agreement”) is entered into by and between Biomerica, Inc., a California Corporation (the “Company”) and Zack Irani (“Employee”). The parties agree that Employee’s employment with the Company is subject to and shall be governed by the following terms and conditions: 1. Duties and Scope of Employment. a. Pos
December 20, 2024	EX-FILING FEES	Filing Fee Table± Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Biomerica, Inc. (Exact name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.08 p
December 20, 2024	S-8	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 BIOMERICA, INC. (Exact name of Registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under THE SECURITIES ACT OF 1933 BIOMERICA, INC. (Exact name of Registrant as specified in its charter) Delaware 95-2645573 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 17571 Von Karman Avenue, Irvine, California 92614 (Address of principal
December 17, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2024 BIOMERICA, INC. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2024 BIOMERICA, INC.
November 25, 2024	EX-FILING FEES	Filing Fee Table± Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Biomerica, Inc. (Exact name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.08 p
November 25, 2024	S-8	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 BIOMERICA, INC. (Exact name of Registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under THE SECURITIES ACT OF 1933 BIOMERICA, INC. (Exact name of Registrant as specified in its charter) Delaware 95-2645573 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 17571 Von Karman Avenue, Irvine, California 92614 (Address of principal
November 14, 2024	SC 13G/A	BMRA / Biomerica, Inc. / GRANAHAN INVESTMENT MANAGEMENT INC/MA Passive Investment SC 13G/A 1 fp0090935-2sc13ga.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 3)* BIOMERICA, INC. (Name of Issuer) Common Stock, par value $0.08 (Title of Class of Securities) 09061H307 (CUSIP Number) S
November 6, 2024	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2024 BIOMERICA, INC.
October 15, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED AUGUST 31, 2024 or ☐ TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED AUGUST 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37863 BIOMERICA, INC. (Ex
September 30, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State
September 20, 2024	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State
August 28, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 For The Fiscal Year Ended May 31, 2024 or ☐ Transition Report Pursuant to Section UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 For The Fiscal Year Ended May 31, 2024 or ☐ Transition Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 For The Transition Period From To Commission File Number: 001-37863 BIOMERICA, INC. (Exact Name of
August 28, 2024	EX-10.8	Employment Agreement dated August 28, 2024 by and between Biomerica Inc. and Gary Lu. Exhibit 10.8 BIOMERICA, INC. Employment Agreement This Employment Agreement (the “Agreement”) is entered into by and between Biomerica, Inc., a California Corporation (the “Company”) and Gary Lu (“Employee”). The parties agree that Employee’s employment with the Company is subject to and shall be governed by the following terms and conditions: 1. Duties and Scope of Employment. a. Positions and Du
June 28, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2024 BIOMERICA, INC.
May 10, 2024	424B5	Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-274729 PROSPECTUS SUPPLEMENT (To Prospectus dated September 28, 2023) $5,500,000 Common Stock On May 10, 2024, we entered into a At Market Issuance Sales Agreement (the “Sales Agreement”) with EF Hutton LLC and R.F. Lafferty & Co., Inc. (each individually, a “Sales Agent” and together, the “Sales Agents”), relating to shares of our common stock
May 10, 2024	EX-1.1	At Market Issuance Sales Agreement, dated May 10, 2024, by and among EF Hutton LLC, R.F. Lafferty & Co. and Biomerica, Inc. Exhibit 1.1 BIOMERICA, INC. Common Stock (par value $0.08 per share) At Market Issuance Sales Agreement May 10, 2024 EF Hutton LLC 590 Madison Avenue, 39th Floor New York, NY 10022 R. F. Lafferty & Co., Inc. 40 Wall Street, 29th Floor New York, NY 10005 Ladies and Gentlemen: Biomerica, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with EF Hutton LLC and R.
May 10, 2024	8-K	Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 BIOMERICA, INC.
April 12, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED FEBRUARY 29, 2024 or ☐ TRANSITION REPORT PURSUA UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED FEBRUARY 29, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37863 BIOMERICA, INC. (Exact name of registrant as specif
February 14, 2024	SC 13G/A	BMRA / Biomerica, Inc. / GRANAHAN INVESTMENT MANAGEMENT INC/MA Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 2)* BIOMERICA, INC. (Name of Issuer) Common Stock, par value $0.08 (Title of Class of Securities) 09061H307 (CUSIP Number) December 31, 2023 (Date of Event W
January 16, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED NOVEMBER 30, 2023 or ☐ TRANSITION REPORT PURSUA UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED NOVEMBER 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37863 BIOMERICA, INC. (Exact name of registrant as specif
December 11, 2023	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2023 BIOMERICA, INC.
October 12, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED AUGUST 31, 2023 or ☐ TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED AUGUST 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37863 BIOMERICA, INC. (Exact name of registrant as specifie
October 12, 2023	EX-3.2	Amended and Restated Bylaws of the Company Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF BIOMERICA, INC. (a Delaware corporation) Adopted by the Board of Directors on July 24, 2023 ARTICLE I Offices 1. The principal office of the Corporation shall be at 251 Little Falls Dr., City of Wilmington, State of Delaware, and the name of the resident agent in charge thereof is CSC-Global. 2. The Corporation may also have an office or offices at such o
September 29, 2023	CORRESP	Biomerica, Inc. 17571 Von Karman Avenue Irvine, California 92614 (949) 645-2111 September 29, 2023 Biomerica, Inc. 17571 Von Karman Avenue Irvine, California 92614 (949) 645-2111 September 29, 2023 SUBMITTED VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Josh Gorsky Re: Biomerica, Inc. Acceleration Request Registration Statement on Form S-3 Filed on September 28, 2023 File No. 333-274729 Ladies and Gentlemen: In
September 28, 2023	S-3	As filed with the Securities and Exchange Commission on September 27, 2023 As filed with the Securities and Exchange Commission on September 27, 2023 Registration No.
September 28, 2023	EX-FILING FEES	Filing Fee Table± Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Biomerica, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1)(2) Fee Rate Amount of Registra
September 27, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State
September 19, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 15, 2023 Date of Report (date of earliest event reported) BIOMERICA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37863 95-2645573 (State or Other Jurisdiction (Commission (IRS Employer of Incorporatio
August 28, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2023 BIOMERICA, INC. (Ex UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2023 BIOMERICA, INC.
August 28, 2023	EX-99.1	Diagnostics Industry Leader Jack Kenny Joins Biomerica’s Board of Directors Exhibit 99.1 NEWS- For Immediate Release Diagnostics Industry Leader Jack Kenny Joins Biomerica’s Board of Directors - Kenny has a proven track record of driving growth at companies within the healthcare space and holds significant management and public company board experience, most recently as CEO of Meridian Bioscience - As CEO Kenny managed the sale of Meridian Biosciences in an all-cash trans
August 25, 2023	EX-21.1	List of Subsidiaries (attached herein). Exhibit 21.1 LIST OF SUBSIDIARIES NAME OF SUBSIDIARY COUNTRY OF INCORPORATION BioEurope GmbH Germany Biomerica de Mexico Mexico
August 25, 2023	EX-3.2	Amended and Restated Bylaws, as adopted on July 24, 2023 (incorporated by reference to Exhibit 3.1 of the Company’s Form 8-K filed July 26, 2023). Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF BIOMERICA, INC. (a Delaware corporation) Adopted by the Board of Directors on July 24, 2023 ARTICLE I Offices 1. The principal office of the Corporation shall be at 251 Little Falls Dr., City of Wilmington, State of Delaware, and the name of the resident agent in charge thereof is CSC-Global. 2. The Corporation may also have an office or offices at such o
August 25, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 For The Fiscal Year Ended May 31, 2023 or ☐ Transition Report Pursuant to Section UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 For The Fiscal Year Ended May 31, 2023 or ☐ Transition Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 For The Transition Period From To Commission File Number: 001-37863 BIOMERICA, INC. (Exact Name of
August 25, 2023	EX-10.6	Employment Agreement, dated March 1, 2023, by and between Biomerica, Inc. and Gary Lu. Exhibit 10.6 17571 VON KARMAN AVE., IRVINE, CALIFORNIA 92614 PH 949-645-2111 FAX 949-553-1231 www.biomerica.com January 31, 2023 Gary Lu, CPA 12136 Ahern Ct. Tustin, CA 92782 Re: Employment Offer Dear Gary: We are pleased to extend to you an offer to join Biomerica, Inc. (the “Company”). The purpose of this letter is to set forth in writing the terms and conditions of your new employment relations
August 25, 2023	EX-10.1	Standard Industrial/Commercial Single-Tenant Lease, dated June 18, 2009, by and between Registrant and CNH, LLC for 17571 Von Karman Avenue, Irvine, CA 92614 (incorporated by reference to Exhibit 10.1 of the Company’s August 31, 2009 Form 10-Q filed October 16, 2009). Exhibit 10.1
August 25, 2023	EX-4.2	Description of Capital Stock. Exhibit 4.2 DESCRIPTION OF CAPITAL STOCK The following is a summary of all material characteristics of the capital stock of Biomerica, Inc. as set forth in our First Amended and Restated Certificate of Incorporation (our “Charter”), Amended and Restated Bylaws (our “Bylaws”), Series A Certificate of Designation, as corrected (the “Certificate of Designation”), and certain provisions of the General
August 25, 2023	EX-3.1	First Amended and Restated Certificate of Incorporation of Registrant filed with the Secretary of State of Delaware on August 1, 2000 (incorporated by reference to Exhibit 3.8 filed with the Registrant’s Annual Report on Form 10-KSB for the fiscal year ended May 31, 2000). Exhibit 3.1 FIRST AMENDED AND RESTATED CERTIFICATE of INCORPORATION OF BIOMERICA, INC. Biomerica, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”) does hereby certify as follows: 1. The Corporation filed its original Certificate of Incorporation with the Secretary of State of the State of Delaware on Septembe
August 25, 2023	EX-10.5	Form of Executive Stock Option Agreement (attached herein). Exhibit 10.5 BIOMERICA, INC. NON-STATUTORY STOCK OPTION AGREEMENT FOR MEMBERS OF THE BOARD OF DIRECTORS Optionee: [[FIRSTNAME]] [[LASTNAME]] No. of shares: [[SHARESGRANTED]] Issue Date: [[GRANTDATE]] Expiration Date: [[GRANTEXPIRATIONDATE]] Exercise Price: [[MARKETPRICEATAWARD]] per share Vesting Schedule: 12 Months from Issue Date [[ALLVESTSEGS]] This Stock Option Agreement (the “Agreement”) is m
July 26, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2023 BIOMERICA, INC. (Exac UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2023 BIOMERICA, INC.
July 26, 2023	EX-3.1	Amended and Restated Bylaws, as adopted on July 24, 2023 AMENDED AND RESTATED BYLAWS OF BIOMERICA, INC. (a Delaware corporation) Adopted by the Board of Directors on July 24, 2023 ARTICLE I Offices 1. The principal office of the Corporation shall be at 251 Little Falls Dr., City of Wilmington, State of Delaware, and the name of the resident agent in charge thereof is CSC-Global. 2. The Corporation may also have an office or offices at such other place o
April 25, 2023	EX-99.1	1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29
April 25, 2023	8-K	Irvine, California 92614 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 25, 2023 Date of Report (date of earliest event reported) BIOMERICA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37863 95-2645573 (State or Other Jurisdiction (Commission (IRS Employer of Incorporation) File Number) Id
April 14, 2023	10-Q	SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED FEBRUARY 28, 2023 or [ ] TRANSITION REPORT PURSUANT TO SECT SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED FEBRUARY 28, 2023 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37863 BIOMERICA, INC. (Exact name of registrant as specified in its
March 7, 2023	EX-99.3	Biomerica Announces Closing of $8 Million Underwritten Public Offering of Common Stock Biomerica Announces Closing of $8 Million Underwritten Public Offering of Common Stock IRVINE, Calif.
March 7, 2023	EX-1.1	Underwriting Agreement, dated March 3, 2023 3,333,333 SHARES of Common Stock BIOMERICA, INC. UNDERWRITING AGREEMENT March 3, 2023 Craig-Hallum Capital Group LLC As the Representative of the Several underwriters, if any, named in Schedule I hereto 222 South Ninth Street, Suite 350 Minneapolis, Minnesota 55402 Ladies and Gentlemen: The undersigned, Biomerica, Inc., a company incorporated under the laws of Delaware (the “Company”), hereby conf
March 7, 2023	EX-99.1	Biomerica Announces Proposed Underwritten Public Offering of Common Stock Biomerica Announces Proposed Underwritten Public Offering of Common Stock IRVINE, Calif.
March 7, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2023 BIOMERICA, INC. (Exac UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2023 BIOMERICA, INC.
March 7, 2023	EX-99.2	Biomerica Announces Pricing of $8 Million Underwritten Public Offering of Common Stock Biomerica Announces Pricing of $8 Million Underwritten Public Offering of Common Stock IRVINE, Calif.
March 7, 2023	424B5	3,333,333 Shares BIOMERICA, INC. 424B5 1 prospectussupplement.htm 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-239980 PROSPECTUS SUPPLEMENT (To Prospectus dated September 30, 2020) 3,333,333 Shares BIOMERICA, INC. We are offering 3,333,333 shares of our common stock, $0.08 par value per share, pursuant to this prospectus supplement. The public offering price for each share of common stock is $2.40. Shares of our co
March 2, 2023	424B5	Subject to Completion Preliminary Prospectus Supplement dated March 2, 2023 Filed Pursuant to Rule 424(b)(5) Registration No. 333-239980 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. Subject to Com
March 2, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2023 BIOMERICA, INC. (Exac UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2023 BIOMERICA, INC.
March 2, 2023	424B5	BIOMERICA, INC. Filed Pursuant to Rule 424(b)(5) Registration No. 333-239980 SUPPLEMENT TO PROSPECTUS SUPPLEMENT DATED JANUARY 22, 2021 (To Prospectus dated September 30, 2020) BIOMERICA, INC. This supplement to prospectus supplement (this “Supplement”) supplements and amends the prospectus supplement dated January 22, 2021 (the “Prospectus Supplement”). This Supplement should be read in conjunction with the Pros
February 14, 2023	SC 13G/A	BMRA / Biomerica, Inc. / GRANAHAN INVESTMENT MANAGEMENT INC/MA Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 1)* BIOMERICA, INC. (Name of Issuer) Common Stock, par value $0.08 (Title of Class of Securities) 09061H307 (CUSIP Number) December 31, 2022 (Date of Event W
February 7, 2023	EX-99.1	1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29
February 7, 2023	8-K	Irvine, California 92614 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 7, 2023 Date of Report (date of earliest event reported) BIOMERICA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37863 95-2645573 (State or Other Jurisdiction (Commission (IRS Employer of Incorporation) File Number)
January 13, 2023	10-Q	SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED NOVEMBER 30, 2022 or [ ] TRANSITION REPORT PURSUANT TO SECT SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED NOVEMBER 30, 2022 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37863 BIOMERICA, INC. (Exact name of registrant as specified in its
December 29, 2022	8-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2022 BIOMERICA, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2022 BIOMERICA, INC.
December 16, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2022 BIOMERICA, INC. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2022 BIOMERICA, INC.
December 16, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2022 BIOMERICA, INC. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2022 BIOMERICA, INC.
December 9, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2022 BIOMERICA, INC. (E UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2022 BIOMERICA, INC.
December 9, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2022 BIOMERICA, INC. (E UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2022 BIOMERICA, INC.
November 14, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 BIOMERICA, INC. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 BIOMERICA, INC.
November 14, 2022	EX-99.1	1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
October 13, 2022	EX-3.1	Amended and Restated Bylaws of the Company AMENDED AND RESTATED BYLAWS OF BIOMERICA, INC. (a Delaware corporation) Adopted by the Board of Directors on October 11, 2022 ARTICLE I Offices 1. The principal office of the Corporation shall be at 251 Little Falls Dr., City of Wilmington, State of Delaware, and the name of the resident agent in charge thereof is CSC-Global. 2. The Corporation may also have an office or offices at such other plac
October 13, 2022	10-Q	SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED AUGUST 31, 2022 or [ ] TRANSITION REPORT PURSUANT TO SECTIO SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED AUGUST 31, 2022 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37863 BIOMERICA, INC. (Exact name of registrant as specified in its c
September 27, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 [X] Filed by the Registrant [ ] Filed by a Party other than the Registrant Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [X]
August 29, 2022	10-K	SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] Annual Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934 For The Fiscal Year Ended May 31, 2022 or [ ] Transition Report Under Section 13 or 15(d) of The Se SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] Annual Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934 For The Fiscal Year Ended May 31, 2022 or [ ] Transition Report Under Section 13 or 15(d) of The Securities Exchange Act Of 1934 For The Transition Period From To Commission File Number: 001-37863 BIOMERICA, INC. (Exact Name of registrant as specifi
April 19, 2022	EX-16.1	Letter from PKF San Diego, LLP dated April 19, 2022. Exhibit 16.1 April 19, 2022 Securities and Exchange Commission 100F Street N.E. Washington, D.C. 20549 Ladies and Gentlemen: We have read Item 4.01 of Form 8-K dated April 19, 2022, of Biomerica, Inc. (the ?Company?) and we agree with the statements relating only to PKF San Diego, LLP contained therein. We have no basis to agree or disagree with other statements of the Company contained therein. /
April 19, 2022	8-K	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2022 BIOMERICA, INC.
April 14, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED FEBRUARY 28, 2022 [ ] TRANSITION R UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED FEBRUARY 28, 2022 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37863 BIOMERICA, INC. - (Exact name of reg
February 14, 2022	SC 13G	BMRA / Biomerica, Inc. / GRANAHAN INVESTMENT MANAGEMENT INC/MA Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 0)* BIOMERICA, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 09061H307 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Fil
February 10, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2022 BIOMERICA, INC.
February 10, 2022	EX-99.1	1 Biomerica Announces Positive Topline Results from the Endpoint Clinical Trial of its InFoods? IBS Treatment for Patients with Irritable Bowel Syndrome InFoods? IBS Diagnostic-Guided Therapy is the first therapy of its kind using science, diet and technology to identify patient specific foods, which when eliminated, help reduce the symptoms of IBS without the use of drugs Multiple endpoints demonst
February 4, 2022	SC 13G/A	BMRA / Biomerica, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* BIOMERICA, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 09061H307 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu
February 4, 2022	SC 13G/A	BMRA / Biomerica, Inc. / Wellington Trust Company, National Association Multiple Common Trust Funds Trust, Micro Cap Equity Portfolio - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* BIOMERICA, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 09061H307 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu
February 4, 2022	SC 13G/A	BMRA / Biomerica, Inc. / WELLINGTON TRUST Co N A - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* BIOMERICA, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 09061H307 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu
January 12, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED NOVEMBER 30, 2021 [ ] TRANSITION R UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED NOVEMBER 30, 2021 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37863 BIOMERICA, INC. - (Exact name of reg
December 16, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2021 BIOMERICA, INC.
December 16, 2021	EX-99.1	Biomerica Announces Preliminary Second Quarter Revenue Increase of Approximately 238%, to approximately $4.6 Million Biomerica Announces Preliminary Second Quarter Revenue Increase of Approximately 238%, to approximately $4.
December 10, 2021	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2021 BIOMERICA, INC.
December 7, 2021	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2021 BIOMERICA, INC.
October 14, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED AUGUST 31, 2021 [ ] TRANSITION REP UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED AUGUST 31, 2021 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37863 BIOMERICA, INC. - (Exact name of regis
October 14, 2021	EX-10.6	Form of Executive Stock Option Agreement (attached herein) FORM OF BIOMERICA, INC. NON-STATUTORY STOCK OPTION AGREEMENT Optionee Name: No. of Option Shares: Issue Date: Expiration Date: Exercise Price: This Stock Option Agreement (the ?Agreement?) is made and entered into effective as of the date set forth on the Signature Page attached hereto by and between Biomerica, Inc., a Delaware corporation (the ?Corporation?), and that person identified on the Sig
October 14, 2021	10-K/A	Table of Contents SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) [X] Annual Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934 For The Fiscal Year Ended May 31, 2021 or [ ] Transition Report Under Section 13 or 15(d) of The Securities Exchange Act Of 1934 For The Transition Period From To Commission File Number: 001-37863 BIOMERICA, INC. (Exact Name of r
October 14, 2021	EX-21.1	Listing of Subsidiaries (attached herein) EXHIBIT 21.1 LIST OF SUBSIDIARIES NAME OF SUBSIDIARY COUNTRY OF INCORPORATION BioEurope GmbH Germany Biomerica de Mexico Mexico
September 30, 2021	8-K	Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 29, 2021 BIOMERICA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37863 95-2645573 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
September 28, 2021	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 [X] Filed by the Registrant [ ] Filed by a Party other than the Registrant Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [X]
August 27, 2021	EX-21.1	Listing of Subsidiaries (attached herein) EXHIBIT 21.1 LIST OF SUBSIDIARIES NAME OF SUBSIDIARY COUNTRY OF INCORPORATION BioEurope GmbH Germany Biomerica de Mexico Mexico
August 27, 2021	EX-10.6	Form of Executive Stock Option Agreement (attached herein) FORM OF BIOMERICA, INC. NON-STATUTORY STOCK OPTION AGREEMENT Optionee Name: No. of Option Shares: Issue Date: Expiration Date: Exercise Price: This Stock Option Agreement (the ?Agreement?) is made and entered into effective as of the date set forth on the Signature Page attached hereto by and between Biomerica, Inc., a Delaware corporation (the ?Corporation?), and that person identified on the Sig
August 27, 2021	10-K	SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] Annual Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934 For The Fiscal Year Ended May 31, 2021 or [ ] Transition Report Under Section 13 or 15(d) of The Se SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] Annual Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934 For The Fiscal Year Ended May 31, 2021 or [ ] Transition Report Under Section 13 or 15(d) of The Securities Exchange Act Of 1934 For The Transition Period From To Commission File Number: 001-37863 BIOMERICA, INC. (Exact Name of registrant as specifi
June 25, 2021	EX-99.1	Biomerica Signs Exclusive Distribution Agreement in Canada for its New and Proprietary Helicobacter Pylori (H. pylori) Test, hp+detect™ NEWS Biomerica Signs Exclusive Distribution Agreement in Canada for its New and Proprietary Helicobacter Pylori (H.
June 25, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 24, 2021 BIOMERICA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37863 95-2645573 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I
May 21, 2021	S-8	2020 Stock Incentive Plan of Registrant (incorporated by reference to Exhibit 10.1 to Registration Statement on Form S-8 filed with the Securities and Exchange Commission on May 21, 2021). UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under THE SECURITIES ACT OF 1933 BIOMERICA, INC. (Exact name of Registrant as specified in its charter) Delaware 95-2645573 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 17571 Von Karman Avenue, Irvine, California 92614 (Address of principal
April 14, 2021	10-Q	Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED FEBRUARY 28, 2021 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37863 BIOMERICA, INC. - (Exact name of reg
February 3, 2021	SC 13G	SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* BIOMERICA, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 09061H307 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule
February 3, 2021	SC 13G/A	SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* BIOMERICA, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 09061H307 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu
February 3, 2021	SC 13G	SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* BIOMERICA, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 09061H307 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule
January 22, 2021	8-K	Financial Statements and Exhibits, Other Events - FORM_8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2021 BIOMERICA, INC.
January 22, 2021	424B5	$15,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-239980 PROSPECTUS SUPPLEMENT (To Prospectus dated September 30, 2020) $15,000,000 Common Stock This prospectus supplement relates to the issuance and sale of up to $15,000,000 of shares of our common stock from time to time through our sales agent, B. Riley Securities, Inc., or B. Riley Securities, the “sales agent.” These sales, if any, will b
January 14, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events - FORM_8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 12, 2021 BIOMERICA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37863 95-2645573 (State or Other Jurisdiction of Incorporation) (Commission File Number)
January 14, 2021	EX-99.1	Biomerica’S Fast 15-Minute Simple to use COVID-19 Antigen RAPID test receives CE Mark Biomerica’S Fast 15-Minute Simple to use COVID-19 Antigen RAPID test receives CE Mark - Biomerica receives first orders and plans to ship tests in coming weeks - Clinical studies demonstrated an overall performance of 94.
January 14, 2021	10-Q	Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED NOVEMBER 30, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37863 BIOMERICA, INC. - (Exact name of reg
December 11, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2020 BIOMERICA, INC.
December 11, 2020	8-K	Submission of Matters to a Vote of Security Holders - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2020 BIOMERICA, INC.
November 30, 2020	SC 13G	BMRA / Biomerica, Inc. / Wellington Trust Company, National Association Multiple Common Trust Funds Trust, Micro Cap Equity Portfolio - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* BIOMERICA, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 09061H307 (CUSIP Number) November 20, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule
October 15, 2020	10-Q	Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED AUGUST 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37863 BIOMERICA, INC. - (Exact name of regis
September 28, 2020	CORRESP	- Biomerica, Inc. 17571 Von Karman Avenue Irvine, California 92614 (949) 645-2111 September 28, 2020 SUBMITTED VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Chris Edwards Re: Biomerica, Inc. Acceleration Request Registration Statement on Form S-3 Originally filed on July 21, 2020 Pre-Effective Amendment No. 1 to Form
September 25, 2020	DEF 14A	- DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 [X] Filed by the Registrant [ ] Filed by a Party other than the Registrant Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [X]
September 11, 2020	S-3/A	- FORM S-3/A As filed with the Securities and Exchange Commission on September 11, 2020 Registration No.
September 11, 2020	CORRESP	- Biomerica, Inc. 17571 Von Karman Avenue Irvine, California 92614 (949) 645-2111 September 11, 2020 SUBMITTED VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Chris Edwards Re: Biomerica, Inc. Withdrawal of Acceleration Request Registration Statement on Form S-3 Originally filed on July 21, 2020 Pre-Effective Amendment
September 9, 2020	CORRESP	- Biomerica, Inc. 17571 Von Karman Avenue Irvine, California 92614 (949) 645-2111 September 9, 2020 SUBMITTED VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Chris Edwards Re: Biomerica, Inc. Acceleration Request Registration Statement on Form S-3 Originally filed on July 21, 2020 Pre-Effective Amendment No. 1 to Form
September 2, 2020	EX-99.1	Biomerica Announces Retirement of Chief Financial Officer (CFO), hiring of new CFO and appointment of new member to the Board of Directors. Biomerica Announces Retirement of Chief Financial Officer (CFO), hiring of new CFO and appointment of new member to the Board of Directors.
September 2, 2020	EX-99.1	1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
September 2, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - FORM 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 1, 2020 Date of Report (date of earliest event reported) BIOMERICA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37863 95-2645573 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer
September 2, 2020	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2020 BIOMERICA, INC.
August 31, 2020	EX-10.8	BIOMERICA, INC. 2020 STOCK INCENTIVE PLAN EXHIBIT A BIOMERICA, INC. 2020 STOCK INCENTIVE PLAN ARTICLE 1. INTRODUCTION. The Plan was adopted by the Board effective February 10, 2020, and submitted to shareholders for approval at the Biomerica Annual Shareholder meeting in December, 2020. The purpose of the Plan is to promote the long-term success of the Company and the creation of stockholder value by (a) encouraging Employees, Outside Dir
August 31, 2020	10-K	Annual Report - FORM 10-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] Annual Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934 For The Fiscal Year Ended May 31, 2020 or [ ] Transition Report Under Section 13 or 15(d) of The Securities Exchange Act Of 1934 For The Transition Period From To Commission File Number: 001-37863 BIOMERICA, INC. (Exact Name of registrant as specifi
July 21, 2020	S-3	- FORM S-3 As filed with the Securities and Exchange Commission on July 20, 2020 Registration No.
June 30, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 29, 2020 BIOMERICA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37863 95-2645573 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I
June 30, 2020	EX-99.1	University of Texas Health Science Center at Houston The University of Texas Health Science Center at Houston joins Biomerica’s InFoods® Irritable Bowel Syndrome ("IBS") Diagnostic-Guided Therapy (“DGT”) clinical trial.
June 17, 2020	EX-99.1	- This high-volume laboratory test will allow for collection of blood samples using a simplified proprietary blood collection device once cleared by the FDA. Biomerica files for FDA Emergency Use Authorization (EUA) of its Unique Laboratory Antibody Test for COVID-19 - This high-volume laboratory test will allow for collection of blood samples using a simplified proprietary blood collection device once cleared by the FDA.
June 17, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 16, 2020 BIOMERICA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37863 95-2645573 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I
June 2, 2020	EX-99.1	1 Mayo Clinic joins Biomerica’s InFoods® Irritable Bowel Syndrome ("IBS") Diagnostic-Guided Therapy clinical trial.
June 2, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 1, 2020 BIOMERICA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37863 95-2645573 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IR
May 11, 2020	EX-99.1	Receives CE mark for Exhibit 99.1 Biomerica Receives CE mark for New High-Volume Version of 10 Minute Test for COVID-19 Exposure and Expands International Distribution o New high-volume production test allows Biomerica to expand international distribution to better meet demand of its 10-minute test for coronavirus exposure. The test can be performed anywhere by trained professionals, e.g. airports, schools, work, doct
May 11, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 7, 2020 BIOMERICA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37863 95-2645573 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Iden
April 14, 2020	10-Q	Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED FEBRUARY 29, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-8765 BIOMERICA, INC. - (Exact name of regist
April 6, 2020	EX-99.1	Biomerica Signs Two Definitive Agreements with Mount Sinai Medical School in New York to Scale-up a Laboratory Version Serological Test for COVID-19 That Enables High-Volume Screenings in Labs Biomerica Signs Two Definitive Agreements with Mount Sinai Medical School in New York to Scale-up a Laboratory Version Serological Test for COVID-19 That Enables High-Volume Screenings in Labs - Price point of this high-volume laboratory version test is expected be as low as $10 per patient - Once developed and scaled-up, Biomerica’s existing production capacity could allow for over 1,000,000 tests per month at its manufacturing facilities in Irvine, California IRVINE, CA-(April 02, 2020) - Biomerica Inc.
April 6, 2020	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2020 BIOMERICA, INC.
March 20, 2020	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2020 BIOMERICA, INC.
March 20, 2020	424B5	$12,500,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-219130 PROSPECTUS SUPPLEMENT (To Prospectus dated July 20, 2017) $12,500,000 Common Stock This prospectus supplement relates to the issuance and sale of up to $12,500,000 of shares of our common stock from time to time through our sales agent, B. Riley FBR, Inc., or B. Riley FBR, the “sales agent.” These sales, if any, will be made pursuant to
March 18, 2020	8-K	Other Events SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 17, 2020 Date of Report (date of earliest event reported) BIOMERICA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 0-8765 95-2645573 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Ident
March 18, 2020	EX-99.1	1 Biomerica Begins Shipping Samples of 10 Minute Test for COVID-19 Virus Exposure - 10-minute test for coronavirus exposure utilizing blood from a finger prick can be performed anywhere by trained professionals, e.
March 4, 2020	EX-99.5	JOINT FILING AGREEMENT EXHIBIT 99.5 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including any and all amendments thereto) with respect to the Common Stock, $0.08 par value per share, of Biomerica, Inc. and further agree that this Joint Filing Agreement sha
March 4, 2020	SC 13D	BMRA / Biomerica, Inc. / Palm Management (us) Llc - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* BIOMERICA, INC. (Name of Issuer) Common Stock, $0.08 par value per share (Title of Class of Securities) 09061H307 (CUSIP Number) Joshua Horowitz, Palm Global Small Cap Master Fund, LP, 19 West Elm Street, Greenwich, CT 06830 (Name, Address and Telephone N
February 27, 2020	EX-99.1	Biomerica Announces $2.0 Million Investment by Palm Global Small Cap Master Fund Biomerica Announces $2.0 Million Investment by Palm Global Small Cap Master Fund February 26, 2020 16:41 ET \| Source: Biomerica, Inc. IRVINE, Calif., Feb. 26, 2020 (GLOBE NEWSWIRE) - Biomerica Inc. (NASDAQ: BMRA) (the “Company” or “Biomerica”) announced today that the Company completed a private placement of $2 million of convertible preferred stock with Palm Global Small Cap Master Fund LP ("Palm
February 27, 2020	EX-10.2	SECTION 1 DEFINITIONS SECTION 2 REGISTRATION RIGHTS SECTION 3 MISCELLANEOUS BIOMERICA, INC. REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made as of February 26, 2020 by and among Biomerica, Inc., a Delaware corporation (the “Company”), and each of the investors set forth on the signature pages hereto (each, the “Investor” and collectively, the “Investors”). RECITALS A. The Company and the Investors are parties to that certain Stoc
February 27, 2020	EX-10.3	Board Observer Agreement Board Observer Agreement This agreement (the “Agreement”) is made effective as of February 26, 2020, by Biomerica, Inc.
February 27, 2020	8-K	Regulation FD Disclosure, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 21, 2020 Date of Report (date of earliest event reported) BIOMERICA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 0-8765 95-2645573 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Id
February 27, 2020	EX-3.1	“If the assets of the Company available for distribution to its stockholders are insufficient to pay the holders of shares of Series A Preferred Stock the full amount to which they are entitled under this Section 4(a), the holders of shares of Series CERTIFICATE OF CORRECTION OF CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF SERIES A 5% CONVERTIBLE PREFERRED STOCK OF BIOMERICA, INC.
February 27, 2020	EX-10.1	BIOMERICA, INC. Stock PURCHASE AGREEMENT BIOMERICA, INC. Stock PURCHASE AGREEMENT This Stock Purchase Agreement (this “Agreement”) is dated as of February 21, 2020 (the “Effective Date”) by and among Biomerica, Inc., a Delaware corporation (the “Company”), and each purchaser listed on the Schedule of Purchasers attached hereto (each, a “Purchaser” and collectively, the “Purchasers”). RECITALS: A. The Company and each Purchaser is executi
January 14, 2020	10-Q	BMRA / Biomerica, Inc. 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED NOVEMBER 30, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-8765 BIOMERICA, INC. - (Exact name of regist
January 9, 2020	EX-99.1	1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
January 9, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 9, 2020 Date of Report (date of earliest event reported) BIOMERICA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 0-8765 95-2645573 (State or Other (Commission (IRS Employer Jurisdiction of File Number) Identification Numb
January 6, 2020	SC 13G	BMRA / Biomerica, Inc. / Intelligent Fanatics Capital Management LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Biomerica, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09061H307 (CUSIP Number) August 15, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i
January 6, 2020	SC 13G	BMRA / Biomerica, Inc. / Intelligent Fanatics Capital Management LLC Passive Investment begin 644 ifcm13gfinal.pdf M)5!$1BTQ+C<-"B6UM;6U#0HQ(# @;V)J#0H\/"]4>7!E+T-A=&%L;V%L@ M," P(#8Q,B W.3)=("]#;VYT96YT+P=NO58!@CP> @(1I&C!R(@#D1 [HI-Z(1R2RQCU"8!^/=ONZIS M,^J>R:?[T9W6##];@QW1R/.5,5W)745/(FY(G4 !(J!35T5A%6:B.OXU7==(X:++96>^1CJ7 MBY?DLFLZ=-#5'4H$LH=IE<;#21I)F6W"J=Y$ADC16$E\OSG\6)..K/%V>"B M>[C)A%PRBAK@DI)4AUYC. !V(1LND5 ;:\A\/7=\F7+Z.R!MEJ;)-F'P# M;]3W\(;78>0=FL%0<+A'U1$P$)Q1+6%)0D6H
December 13, 2019	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2019 BIOMERICA, INC.
October 15, 2019	10-Q	BMRA / Biomerica, Inc. 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED AUGUST 31, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-8765 BIOMERICA, INC. - (Exact name of registra
September 24, 2019	DEF 14A	BMRA / Biomerica, Inc. DEF 14A - - DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 [X] Filed by the Registrant [ ] Filed by a Party other than the Registrant Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [X]
September 4, 2019	8-K	Other Events SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 4, 2019 Date of Report (date of earliest event reported) BIOMERICA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 0-8765 95-2645573 (State or Other (Commission (IRS Employer Jurisdiction of File Number) Identification Nu
August 29, 2019	10-K	BMRA / Biomerica, Inc. 10-K - Annual Report - FORM 10-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] Annual Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934 For The Fiscal Year Ended May 31, 2019 or [ ] Transition Report Under Section 13 or 15(d) of The Securities Exchange Act Of 1934 For The Transition Period From To Commission File Number: 0-8765 BIOMERICA, INC. (Exact Name of registrant as specified
June 5, 2019	8-K	Other Events SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 31, 2019 Date of Report (date of earliest event reported) BIOMERICA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 0-8765 95-2645573 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identif
April 15, 2019	10-Q	BMRA / Biomerica, Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED FEBRUARY 28, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-8765 BIOMERICA, INC. - (Exact name of regist
April 9, 2019	8-K	Other Events SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 5, 2019 Date of Report (date of earliest event reported) BIOMERICA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 0-8765 95-2645573 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identi
March 21, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2019 BIOMERICA, INC.
February 12, 2019	SC 13G/A	BMRA / Biomerica, Inc. / GELBAND ALAN - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* BIOMERICA, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 09061H307 (CUSIP Number) ALAN GELBAND 750 Third Avenue New York, NY 10007 (212) 688-2808 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Commun
January 14, 2019	10-Q	BMRA / Biomerica, Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED NOVEMBER 30, 2018 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-8765 BIOMERICA, INC. - (Exact name of regist
December 14, 2018	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2017 BIOMERICA, INC.
October 15, 2018	10-Q	BMRA / Biomerica, Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED AUGUST 31, 2018 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-8765 BIOMERICA, INC. - (Exact name of registra
September 28, 2018	DEF 14A	BMRA / Biomerica, Inc. DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 [X] Filed by the Registrant [ ] Filed by a Party other than the Registrant Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [X]
September 28, 2018	EX-99.1	EX-99.1
September 28, 2018	8-K	Regulation FD Disclosure, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 27, 2018 Date of Report (date of earliest event reported) BIOMERICA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 0-8765 95-2645573 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer I
August 29, 2018	10-K	BMRA / Biomerica, Inc. FORM 10-K (Annual Report) SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] Annual Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934 For The Fiscal Year Ended May 31, 2018 or [ ] Transition Report Under Section 13 or 15(d) of The Securities Exchange Act Of 1934 For The Transition Period From To Commission File Number: 0-8765 BIOMERICA, INC. (Exact Name of registrant as specified
August 25, 2018	8-K	Other Events SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 22, 2018 Date of Report (date of earliest event reported) BIOMERICA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 0-8765 95-2645573 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Iden
May 10, 2018	S-8	2017 Stock Incentive Plan of Registrant (incorporated by reference to Exhibit 10.1 to Registration Statement on Form S-8 filed with the Securities and Exchange Commission on May 10, 2018). As filed with the Securities and Exchange Commission on May 10, 2018 Registration No.
April 16, 2018	10-Q	BMRA / Biomerica, Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED FEBRUARY 28, 2018 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-8765 BIOMERICA, INC. - (Exact name of regist
March 8, 2018	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2017 BIOMERICA, INC.
March 8, 2018	EX-99	Mexico’s COFEPRIS (Mexico’s equivalent of the FDA) approves Biomerica colorectal screening test to help identify the early warning signs of colorectal cancer. -Biomerica ships first order to Mexico- EX-99 2 Exhibit99.htm EXHIBIT 99 NEWS - For Immediate Release Mexico’s COFEPRIS (Mexico’s equivalent of the FDA) approves Biomerica colorectal screening test to help identify the early warning signs of colorectal cancer. -Biomerica ships first order to Mexico- Irvine, California – March 8, 2018 - Biomerica, Inc. (Nasdaq: BMRA) announced the Mexico’s COFEPRIS (Comisión Federal para la Protección co
January 17, 2018	10-Q/A	BMRA / Biomerica, Inc. FORM 10-Q/A (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED NOVEMBER 30, 2017 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-8765 BIOMERICA, INC. - (Exact name of regi
January 16, 2018	10-Q	BMRA / Biomerica, Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED NOVEMBER 30, 2017 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-8765 BIOMERICA, INC. - (Exact name of regist
January 10, 2018	8-K	Submission of Matters to a Vote of Security Holders Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2017 BIOMERICA, INC.
January 5, 2018	SC 13G/A	BMRA / Biomerica, Inc. / GELBAND ALAN - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* BIOMERICA, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 09061H307 (CUSIP Number) ALAN GELBAND 750 Third Avenue New York, NY 10007 (212) 688-2808 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Commun
December 2, 2017	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits form 8k UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2017 BIOMERICA, INC.
December 2, 2017	EX-1.01	BIOMERICA, INC. Common Stock (par value $0.08 per share) sales agreement BIOMERICA, INC. Common Stock (par value $0.08 per share) At Market Issuance Sales Agreement December 1, 2017 B. Riley FBR, Inc. 299 Park Avenue, 7th Floor New York, NY, 10171 Ladies and Gentlemen: Biomerica, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with B. Riley FBR, Inc. (the ?Agent?) as follows: 1. Issuance and Sale of Shares. The pa
December 2, 2017	424B5	PROSPECTUS SUPPLEMENT (To Prospectus dated July 20, 2017) Common Stock Prospectus Filed Pursuant to Rule 424(b)(5) Registration No. 333-219130 PROSPECTUS SUPPLEMENT (To Prospectus dated July 20, 2017) $7,000,000 Common Stock This prospectus supplement relates to the issuance and sale of up to $7,000,000 of shares of our common stock from time to time through our sales agent, B. Riley FBR, Inc., or B. Riley FBR, the ?sales agent.? These sales, if any, will be made pur
October 16, 2017	10-Q	BMRA / Biomerica, Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED AUGUST 31, 2017 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-8765 BIOMERICA, INC. - (Exact name of registra
September 28, 2017	DEF 14A	Biomerica DEF 14A DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 [X] Filed by the Registrant [ ] Filed by a Party other than the Registrant Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(
August 29, 2017	10-K	BMRA / Biomerica, Inc. FORM 10-K (Annual Report) SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] Annual Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934 For The Fiscal Year Ended May 31, 2017 or [ ] Transition Report Under Section 13 or 15(d) of The Securities Exchange Act Of 1934 For The Transition Period From To Commission File Number: 0-8765 BIOMERICA, INC. (Exact Name of registrant as specified
July 18, 2017	CORRESP	Biomerica ESP BIOMERICA, INC. 17571 Von Karman Ave. Irvine, CA 92614 July 18, 2017 SUBMITTED VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Tim Buchmiller Re: Biomerica, Inc. Registration Statement on Form S-3 (File No. 333-219130) Acceleration Request Requested Date: July 20, 2017 Requested Time: 5:00 P.M. Eastern Time Ladies an
June 30, 2017	S-3	Biomerica FORM S-3 form S-3 As filed with the Securities and Exchange Commission on June 30, 2017 Registration No.
April 14, 2017	10-Q	Biomerica FORM 10-Q (Quarterly Report) Form 10Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED FEBRUARY 28, 2017 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-8765 BIOMERICA, INC. - (Exact name
January 17, 2017	10-Q	Biomerica FORM 10-Q (Quarterly Report) FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED NOVEMBER 30, 2016 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-8765 BIOMERICA, INC. - (Exact name
January 6, 2017	SC 13G/A	BMRA / Biomerica, Inc. / GELBAND ALAN - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* BIOMERICA, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 09061H307 (CUSIP Number) ALAN GELBAND 750 Third Avenue New York, NY 10007 (212) 688-2808 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Commun
October 17, 2016	10-Q	Biomerica FORM 10-Q (Quarterly Report) Form 10Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED AUGUST 31, 2016 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-8765 BIOMERICA, INC. - (Exact name of
September 28, 2016	DEF 14A	Biomerica DEF 14A DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 [X] Filed by the Registrant [ ] Filed by a Party other than the Registrant Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)
September 12, 2016	EX-99	EX-99 EX-99 2 exhibit99.htm EXHIBIT 99
September 12, 2016	8-K	Other Events FORM 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 12, 2016 Date of Report (date of earliest event reported) BIOMERICA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 0-8765 95-2645573 (State or Other (Commission (IRS Employer Jurisdiction of File Number) Identif
August 29, 2016	10-K	Biomerica FORM 10-K (Annual Report) Form 10K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] Annual Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934 For The Fiscal Year Ended May 31, 2016 or [ ] Transition Report Under Section 13 or 15(d) of The Securities Exchange Act Of 1934 For The Transition Period From To Commission File Number: 0-8765 BIOMERICA, INC. (Exact Name of registrant as s
August 23, 2016	8-A12B	Form 8-A Form 8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOMERICA, INC.
August 23, 2016	8-A12B	Form 8-A Form 8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOMERICA, INC.
August 10, 2016	8-K	Other Events Form 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 10, 2016 Date of Report (date of earliest event reported) BIOMERICA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 0-8765 95-2645573 (State or Other (Commission (IRS Employer Jurisdiction of File Number) Identifica
August 10, 2016	8-K	Other Events Form 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 10, 2016 Date of Report (date of earliest event reported) BIOMERICA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 0-8765 95-2645573 (State or Other (Commission (IRS Employer Jurisdiction of File Number) Identifica
July 18, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers FORM 8K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 14, 2016 Date of Report (date of earliest event reported) BIOMERICA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 0-8765 95-2645573 (State or Other (Commission (IRS Employer Jurisdiction of File Number) Identificatio
May 26, 2016	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 25, 2016 Date of Report (date of earliest event reported) BIOMERICA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 0-8765 95-2645573 (State or Other (Commission File Number) (IRS Employer Jurisdiction of Incorporation) Identif
April 14, 2016	10-Q	Biomerica FORM 10-Q (Quarterly Report) FORM 10Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED FEBRUARY 29, 2016 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-8765 BIOMERICA, INC. - (Exact name
March 15, 2016	EX-99	Thank you. First presentation to an investor group EXHIBIT 99 * Thank you. First presentation to an investor group * * * * * *
March 15, 2016	8-K	Other Events FORM 8K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 15, 2016 Date of Report (date of earliest event reported) BIOMERICA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 0-8765 95-2645573 (State or Other (Commission (IRS Employer Jurisdiction of File Number) Identificati
February 5, 2016	SC 13G/A	BMRA / Biomerica, Inc. / GELBAND ALAN - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* BIOMERICA, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 09061H307 (CUSIP Number) ALAN GELBAND 750 Third Avenue New York, NY 10007 (212) 688-2808 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Commun
January 14, 2016	10-Q	BMRA / Biomerica, Inc. 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED NOVEMBER 30, 2015 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-8765 BIOMERICA, INC. - (Exact name of regist
October 15, 2015	10-Q	Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED AUGUST 31, 2015 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-8765 BIOMERICA, INC. - (Exact name of registra
September 28, 2015	DEF 14A	Biomerica DEF 14A DEF14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 [X] Filed by the Registrant [ ] Filed by a Party other than the Registrant Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2
August 31, 2015	10-K	SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] Annual Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934 For The Fiscal Year Ended May 31, 2015 [ ] Transition Report Under Section 13 or 15(d) of The Secur SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] Annual Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934 For The Fiscal Year Ended May 31, 2015 or [ ] Transition Report Under Section 13 or 15(d) of The Securities Exchange Act Of 1934 For The Transition Period From To Commission File Number: 0-8765 BIOMERICA, INC. (Exact Name of registrant as specified
May 22, 2015	S-8	2014 Stock Incentive Plan of Registrant (incorporated by reference to Exhibit 10.1 to Registration Statement on Form S-8 filed with the Securities and Exchange Commission on May 22, 2015). Form S-8 As filed with the Securities and Exchange Commission on May 20, 2015 Registration No.
April 14, 2015	10-Q	Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED FEBRUARY 28, 2015 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-8765 BIOMERICA, INC. - (Exact name of regist
January 14, 2015	10-Q	Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED NOVEMBER 30, 2014 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-8765 BIOMERICA, INC. - (Exact name of regist
December 24, 2014	SC 13G	BMRA / Biomerica, Inc. / GELBAND ALAN - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* BIOMERICA, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 09061H307 (CUSIP Number) ALAN GELBAND 750 Third Avenue New York, NY 10007 (212) 688-2808 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communica
October 15, 2014	10-Q	Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED AUGUST 31, 2014 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-8765 BIOMERICA, INC. - (Exact name of registra
September 29, 2014	DEF 14A	BMRA / Biomerica, Inc. DEF 14A - - DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 [X] Filed by the Registrant [ ] Filed by a Party other than the Registrant Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [X]
August 29, 2014	10-K	Annual Report - FORM 10-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] Annual Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934 For The Fiscal Year Ended May 31, 2014 or [ ] Transition Report Under Section 13 or 15(d) of The Securities Exchange Act Of 1934 For The Transition Period From To Commission File Number: 0-8765 BIOMERICA, INC. (Exact Name of registrant as specified
April 14, 2014	10-Q	Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED FEBRUARY 28, 2014 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-8765 BIOMERICA, INC. - (Exact name of regist
January 14, 2014	10-Q	Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED NOVEMBER 30, 2013 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-8765 BIOMERICA, INC. - (Exact name of regist
October 15, 2013	10-Q	Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED AUGUST 31, 2013 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-8765 BIOMERICA, INC. - (Exact name of registra
September 30, 2013	DEF 14A	- DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 [X] Filed by the Registrant [ ] Filed by a Party other than the Registrant Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [X]
August 29, 2013	10-K	SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] Annual Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934 For The Fiscal Year Ended May 31, 2013 [ ] Transition Report Under Section 13 or 15(d) of The Secur SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] Annual Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934 For The Fiscal Year Ended May 31, 2013 or [ ] Transition Report Under Section 13 or 15(d) of The Securities Exchange Act Of 1934 For The Transition Period From To Commission File Number: 0-8765 BIOMERICA, INC. (Exact Name of registrant as specified
April 15, 2013	10-Q	Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED FEBRUARY 28, 2013 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-8765 BIOMERICA, INC. - (Exact name of regist
April 15, 2013	8-K	Unregistered Sales of Equity Securities - FORM 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 8, 2013 Date of Report (date of earliest event reported) BIOMERICA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 0-8765 95-2645573 (State or Other (Commission (IRS Employer Jurisdiction of File Number) Identification Number
April 8, 2013	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement - FORM 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 2, 2013 Date of Report (date of earliest event reported) BIOMERICA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 0-8765 95-2645573 (State or Other (Commission (IRS Employer Jurisdiction of File Number) Identification Number
January 14, 2013	10-Q	Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED NOVEMBER 30, 2012 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-8765 BIOMERICA, INC. (Exact name of registra
October 12, 2012	10-Q	Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED AUGUST 31, 2012 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-8765 BIOMERICA, INC. (Exact name of registrant
September 28, 2012	DEF 14A	- DEF 14A biomericadef14a.htm - Generated by SEC Publisher for SEC Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 [X] Filed by the Registrant [ ] Filed by a Party other than the Registrant Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Us
August 29, 2012	10-K	Annual Report - FORM 10-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] Annual Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934 For The Fiscal Year Ended May 31, 2012 or [ ] Transition Report Under Section 13 or 15(d) of The Securities Exchange Act Of 1934 For The Transition Period From To Commission File Number: 0-8765 BIOMERICA, INC. (Exact Name of registrant as specified
April 16, 2012	10-Q	Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED FEBRUARY 29, 2012 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-8765 BIOMERICA, INC. - (Exact name of regist
February 9, 2012	S-8	- FORM S-8 s8.htm - Generated by SEC Publisher for SEC Filing As filed with the Securities and Exchange Commission on February 8, 2012 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Biomerica, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 95-2645573 (State or Other Jurisdicti
January 17, 2012	10-Q	Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED NOVEMBER 30, 2011 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-8765 BIOMERICA, INC. - (Exact name of regist
October 27, 2011	10-Q/A	Quarterly Report - FORM 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED AUGUST 31, 2011 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-8765 BIOMERICA, INC. - (Exact name of regist
October 17, 2011	10-Q	Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED AUGUST 31, 2011 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-8765 BIOMERICA, INC. - (Exact name of registra
September 28, 2011	DEF 14A	- PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 [X] Filed by the Registrant [ ] Filed by a Party other than the Registrant Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [X]
August 30, 2011	10-K	Annual Report - FORM 10-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] Annual Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934 For The Fiscal Year Ended May 31, 2011 or [ ] Transition Report Under Section 13 or 15(d) of The Securities Exchange Act Of 1934 For The Transition Period From To Commission File Number: 0-8765 BIOMERICA, INC. (Exact Name of registrant as specified
August 30, 2011	NT 10-K	- FORM NT 10-K U.S. SECURITIES AND EXCHANGE COMMISSION +-+ WASHINGTON D.C. 20549 \| OMB Number \| \| 3235-0058 \| FORM 12b-25 \| expires \| NOTIFICATION OF LATE FILING \| 01/31/2002 \| \| \| \| SEC File # \| \| 000- \| \| CUSIP # \| \| \| +-+ check box Form 10-K [x] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form N-SAR [ ] Form N-CSR [ ] For Period Ended: May 31, 2011 - [ ] Transition Report on Form 10-K [ ] Transition Report on F
April 14, 2011	10-Q	Quarterly Report - BIOMERICA, INC. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PERSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED FEBRUARY 28, 2011 OR [] TRANSITION REPORT PERSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-8765 BIOMERICA, INC. (Exact name of registrant as specified
January 14, 2011	10-Q	Quarterly Report - BIOMERICA, INC. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED NOVEMBER 30, 2010 OR o TRANSITION REPORT PERSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-8765 BIOMERICA, INC. (Exact name of registrant as specified in
October 15, 2010	10-Q	Quarterly Report - BIOMERICA 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED AUGUST 31, 2010 OR [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-8765 BIOMERICA, INC. (Exact name of registrant
September 29, 2010	DEF 14A	- BIOMERICA, INC. DEF 14A 1 biomericadef14a.htm BIOMERICA, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Prelimin
September 27, 2010	SC 13G	Passive Investment - BROADOAK FUND UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* (Name of Issuer) Biomerica, Inc. (Title of Class of Securities) Common Stock (CUSIP Number) 09061H307 (Date of Event Which Requires Filing of this Statement) 12/31/2009 Check the appropriate box to designate the rule pursuant to which this Schedule is fil
August 30, 2010	10-K	Annual Report - BIOMERICA 10-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] Annual Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934 For The Fiscal Year Ended May 31, 2010 or [] Transition Report Under Section 13 or 15(d) of The Securities Exchange Act Of 1934 For The Transition Period From To Commission File Number: 0-8765 BIOMERICA, INC. (Exact Name of registrant as specified i
August 30, 2010	EX-99.3	BIOMERICA, INC. AND SUBSIDIARIES TABLE OF CONTENTS EXHIBIT 99.3 BIOMERICA, INC. AND SUBSIDIARIES TABLE OF CONTENTS Report Of Independent Registered Public Accounting Firm FS-2 CONSOLIDATED FINANCIAL STATEMENTS Consolidated Balance Sheets as of May 31, 2010 and 2009 FS-3 Consolidated Statements of Operations and Comprehensive Income(Loss) for the Years Ended May 31, 2010 and 2009 FS-4 - FS-5 Consolidated Statements of Shareholders' Equity for the Y
October 16, 2009	EX-10.1	Standard Industrial/Commercial Single-Tenant Lease for 17571 Von Karman Avenue, Irvine, CA 92614, incorporated by reference to Exhibit 10.1 of the Company's August 31, 2009 Form 10Q filed October 15, 2009. Exhibit 10.1 AIR COMMERCIAL REAL ESTATE ASSOCIATION STANDARD INDUSTRIAL/COMMERCIAL SINGLE-TENANT LEASE - - GROSS (DO NOT USE THIS FORM FOR MULTI-TENANT BUILDINGS) 1. Basic Provisions ("Basic Provisions"). 1.1 Parties: This Lease ("Lease"), dated for reference purposes only June 18, 2009 is made by and between CNH, LLC, a California limited liability company &# 160; ("Lessor") and Biomerica, Inc.,
November 7, 2007	SC 13G	Passive Investment - SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Biomerica, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09061H 30 7 (CUSIP Number) 10/31/07 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is file
May 30, 2007	S-8	- As filed with the Securities and Exchange Commission on May 30, 2007 Registration No.
July 10, 2003	DEFR14A	- SCHEDULE 14A (RULE 14A-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 ================================================================================ Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [X] Definitive Proxy Statement [ ] Definitive Additional Materials [ ] Soliciting Material Pursuant to Rule 14a-11(c) or Rule 14a-12 BIOMERICA, INC.
October 15, 2002	10QSB	- FORM 10-QSB SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For Quarter Ended August 31, 2002 Commission File No. 0-8765 - - BIOMERICA, INC. - - (Exact name of registrant as specified in its charter) Delaware 95-2645573 - - (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Iden

BMRA / Biomerica, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)